Paradigm Biocapital Advisors LP Janux Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,920,258 shares of JANX stock, worth $68.1 Million. This represents 3.15% of its overall portfolio holdings.
Number of Shares
2,920,258
Previous 3,329,909
12.3%
Holding current value
$68.1 Million
Previous $89.9 Million
24.97%
% of portfolio
3.15%
Previous 4.61%
Shares
5 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$261 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$104 Million0.05% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$58.9 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$54.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$51 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $971M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...